ReviewClinical and experimental immunology2009
Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.
Review in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06089122 (Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG in Patients With Primary Immunodeficiency), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG in Patients With Primary Immunodeficiency
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review.Advances in rheumatology (London, England) · 2025Pooled it
- Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.International journal of hematology · 2011Trial
- A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD.International journal of chronic obstructive pulmonary diseaseTrial
- Medical haematology: Repositioning haematology at the centre of medicine.British journal of haematology · 2026Review
- Physiologically Based Pharmacokinetic Model for Prediction of Immunoglobulins Exposure in Pregnant Women.Antibodies (Basel, Switzerland) · 2025Article
- The hexapeptide functionalized gold nanoparticles protect against sepsis-associated encephalopathy by forming specific protein corona and regulating macrophage activation.Materials today. Bio · 2025Article
- Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study.Journal of medical virology · 2024Article
- Serum immunoglobulin levels in group E of chronic obstructive pulmonary disease: insights for clinical management and immunoglobulin therapy strategies.BMC pulmonary medicine · 2024Observational
- Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.Immunotherapy · 2024Review
- A database of anti-coronavirus peptides.Scientific data · 2022Article
- Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese.Frontiers in immunology · 2022Observational
- Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.Frontiers in immunology · 2022Article
- Efficacy of human immunoglobulin injection and effects on serum inflammatory cytokines in neonates with acute lung injury.Experimental and therapeutic medicine · 2021Article
- COVID-19: The Immune Responses and Clinical Therapy Candidates.International journal of molecular sciences · 2020Review
- Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019.Journal of clinical pharmacy and therapeutics · 2020Article
- Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence.Antibodies (Basel, Switzerland) · 2020Review
- Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.Expert review of proteomics · 2020Review
- Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment.Journal of central nervous system disease · 2019Review
- Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.Biotechnology and bioengineering · 2018Article
- Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets.BMC systems biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical use of intravenous immunoglobulin (IVIg) has expanded beyond its traditional place in the treatment of patients with primary immunodeficiencies. Due to its multiple anti-inflammatory and immunomodulatory properties, IVIg is used successfully in a wide range of autoimmune and inflammatory conditions. Recognized autoimmune indications include idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome and other autoimmune neuropathies, myasthenia gravis, dermatomyositis and several rare diseases. Several other indications are currently under investigation and require additional studies to establish firmly the benefit of IVIg treatment. Increasing attention is being turned to the use of IVIg in combination with other agents, such as immunosuppressive agents or monoclonal antibodies. For example, recent studies suggest that combination therapy with IVIg and rituximab (an anti-CD20 monoclonal antibody) may be effective for treatment of autoimmune mucocutaneous blistering diseases (AMBDs), with sustained clinical remission. The combination of IVIg and rituximab has also been used in the setting of organ transplantation. Firstly, IVIg +/- rituximab has been administered to highly human leucocyte antigen (HLA)-sensitized patients to reduce anti-HLA antibody levels, thereby allowing transplantation in these patients. Secondly, IVIg in combination with rituximab is effective in the treatment of antibody-mediated rejection following transplantation. Treatment with polyclonal IVIg is a promising adjunctive therapy for severe sepsis and septic shock, but its use remains controversial and further study is needed before it can be recommended routinely. This review covers new developments in these fields and highlights the broad range of potential therapeutic areas in which IVIg may have a clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.